Table 2 Characteristics of SCD and TDT/NTDT patients with COVID- 19

Age (years)

22.2 (16.7)

41.3 (14.2)

33 (18.2)

 < 0.001

620

BMI

20.7 (4.4)

23.6 (4.2)

22.4 (4.6)

 < 0.001

543

Ferritin level (ng/ml) *

474.5 (686.1)

1238 (1654.5)

917.1 (1422.1)

 < 0.001

510

LDH (U/L) *

447.2 (204.2)

346 (200.5)

396.9 (208)

 < 0.001

424

C-reactive protein (mg/dL)

3.3 (10.9)

2.3 (10.4)

3 (10.6)

0.04

210

Treatment

Antibiotic Prophylaxis *

69 (38.5%)

3 (1.4%)

72 (18.1%)

 < 0.001

398

Crizanlizumab

7 (3.9%)

0 (0%)

7 (1.8%)

0.003

398

Chronic transfusion (simple transfusion) *

4 (2.2%)

83 (37.9%)

87 (21.9%)

 < 0.001

398

Chronic transfusion (RCE)

20 (11.2%)

2 (0.9%)

22 (5.5%)

 < 0.001

398

Deferasirox *

4 (2.2%)

91 (41.6%)

95 (23.9%)

 < 0.001

398

Deferiprone

2 (1.1%)

85 (38.8%)

87 (21.9%)

 < 0.001

398

Deferoxamine *

1 (0.6%)

83 (37.9%)

84 (21.1%)

 < 0.001

398

Hydroxyurea *

124 (69.3%)

8 (3.7%)

132 (33.2%)

 < 0.001

398

Luspatercept

0 (0%)

6 (2.7%)

6 (1.5%)

0.035

398

Splenectomy *

43 (16.3%)

163 (45.5%)

206 (33.1%)

 < 0.001

622

Comorbidities *

113 (43.6%)

195 (54.5%)

308 (49.9%)

0.01

617

ACS

25 (9.3%)

0 (0%)

25 (3.9%)

 < 0.001

642

Arrhythmia

1 (0.4%)

32 (8.6%)

33 (5.1%)

 < 0.001

642

DM *

3 (1.1%)

46 (12.3%)

49 (7.6%)

 < 0.001

642

Liver cirrhosis

1 (0.4%)

16 (4.3%)

17 (2.6%)

0.005

642

ANH

8 (3%)

0 (0%)

8 (1.2%)

 < 0.001

642

Smoking

1 (0.4%)

12 (3.2%)

13 (2%)

0.025

642

COVID- 19 vaccination *

29 (13.6%)

143 (44.5%)

172 (32.1%)

 < 0.001

535